Close

TPI to start test runs at JCM manufacturing plant

Related stories

New Syngene biologics manufacturing facility to be operational for US and European customers from mid-year

At DCAT 2024 global bio/pharmaceutical manufacturing forum, Syngene International,...

ST Pharm breaks ground on 2nd oligonucleotide manufacturing plant

ST Pharm said it has taken its first step...

Elevating Biopharmaceutical Projects With The Right CDMO

In the biopharma industry, selecting the right contract development...

Biovian announces over €50 million investment in manufacturing facility in Turku, Finland

Biovian, a leading contract development and manufacturing organization (CDMO)...

New PAT – Based Strategy Stops Membrane Fouling In SP – TFF

A recent article published in the Journal of Membrane...

China-based drug manufacturer Tianyin Pharmaceutical (TPI) is set to start test run at its 250-ton Jiangchuan Macrolide facility (JCM) for good manufacturing practice (GMP) certification process.
The company will conduct the test runs by the end of this month to investigate whether the plant is maintaining GMP.Additionally, the company will also verify its performance, efficiency, reliability and safety of the Azithromycin API manufacturing at JCM.Following the successful completion of the test runs the company will initiate the GMP certification process.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories